Predict your next investment

HEALTHCARE | Pharmaceutical Distribution & Wholesale
xtlbio.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

9/27/2000

Market Cap

0.06B

About XTL Biopharmaceuticals

XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

XTL Biopharmaceuticals Headquarter Location

Ra'anana, 4365603,

Israel

+972-9-955-7080

Latest XTL Biopharmaceuticals News

XTLB Stock Price Increases Over 100% Pre-Market: Why It Happened

Mar 5, 2021

The stock price of XTL Biopharmaceuticals (NASDAQ: XTLB) has increased by over 100% pre-market. This is why it happened. The stock price of XTL Biopharmaceuticals (NASDAQ: XTLB) – a biopharmaceutical company that engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases – has increased by over 100% pre-market as of 6:40 AM ET. There is no notable news or SEC reports from the company so it seems like there are external factors at play. The report points out that the global recombinant proteins market is projected to reach $1.7 billion by 2026 from $1 billion in 2021 at a CAGR of 9.8% during the forecast period. And the market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industry academia collaborations, and the patent expiry of biologic products. The emerging markets in Asian countries and the rising focus on personalized medicine and protein therapeutics are other factors expected to offer strong growth opportunities for players in the recombinant proteins market. And the declining cost of recombinant proteins may restrict market growth to a certain extent. “Recombinant Human Erythropoietin (“rHuEPO”), a known agent for anemia, is being developed to prolong the survival of patients with advanced Multiple Myeloma (‘MM’). Our rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the FDA in 2011,” says the pipeline section of the XTL Biopharmaceuticals website. Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

XTL Biopharmaceuticals Patents

XTL Biopharmaceuticals has filed 8 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Monoclonal antibodies
  • Autoantibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/15/2005

12/11/2012

Nitrogen heterocycles, Oxygen heterocycles, Indoles, Drug discovery, Pyrazoles

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/15/2005

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/11/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Nitrogen heterocycles, Oxygen heterocycles, Indoles, Drug discovery, Pyrazoles

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

XTL Biopharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

XTL Biopharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.